Braveheart Bio, Inc. (BRVE)
NASDAQ: BRVE · Real-Time Price · USD
26.95
+0.67 (2.55%)
Sep 2, 2026, 4:00 PM EDT - Market closed
Braveheart Bio Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Braveheart Bio stock has a consensus rating of "Strong Buy" and an average price target of $44.33. The average 1-year stock price forecast is 64.49% higher than the current stock price, while the lowest is $40 (+48.42%) and the highest is $48 (+78.11%).
Price Target: $44.33 (+64.49%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Braveheart Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $40 | Buy | Initiates | $40 | +48.42% | Aug 31, 2026 |
| TD Cowen | TD Cowen | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Aug 31, 2026 |
| Jefferies | Jefferies | Buy Initiates $48 | Buy | Initiates | $48 | +78.11% | Aug 31, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Initiates $45 | Buy | Initiates | $45 | +66.98% | Aug 31, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Initiates $48 | Buy | Initiates | $48 | +78.11% | Aug 31, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.44
EPS Next Year
-2.17
from -1.44
EPS and Forward PE are based on non-GAAP adjusted numbers.